Clinical phase III studies with CTLA-4 ICM ipilimumab (Yervoy®) in metastatic melanoma have shown superiority in survival over tumour vaccination [8, 9] and a survival benefit in combination with chemotherapy versus chemotherapy alone [10]. This evidence concerns the gene CTLA4 and neoplasm.